Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
Baxter
Merck
Harvard Business School

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,549,913

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,549,913
Title:Treatment of circadian rhythm disorders
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s): Dressman; Marlene Michelle (Germantown, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:14/374,257
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,549,913
Patent Claims: 1. A method of entraining a patient's cortisol circadian rhythm to a 24-hour circadian rhythm and maintaining said 24-hour circadian rhythm, the method comprising: treating the patient by orally administering to the patient tasimelteon once daily before a target bedtime.

2. The method of claim 1, wherein the patient is light perception impaired (LPI).

3. The method of claim 1, wherein the patient is totally blind.

4. The method of claim 1, wherein the patient suffers from Non-24-Hour Sleep-Wake Disorder.

5. The method of claim 1, wherein the 24-hour circadian rhythm comprises a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours.

6. The method of claim 1, wherein the tasimelteon is orally administered 0.5 hours to 1.5 hours before the target bedtime.

7. The method of claim 1, wherein treatment is initiated on a day in which the patient's urinary cortisol acrophase is predicted to be within about 5.5 hours before a target wake time and about 2.5 hours after the target wake time.

8. The method of claim 1, wherein treatment is initiated on a day in which the patient's urinary aMT6s acrophase is predicted to be within about 5.5 hours before a target wake time and about 2.5 hours after the target wake time.

9. The method of claim 1, wherein the administering includes administering between about 10 mg and 100 mg of tasimelteon.

10. The method of claim 1, wherein the administering includes administering between about 20 mg and about 50 mg of tasimelteon.

11. The method of claim 1, wherein the administering includes administering about 20 mg of tasimelteon.

12. The method of claim 4, wherein the 24-hour circadian rhythm comprises a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours.

13. The method of claim 5, wherein the tasimelteon is orally administered 0.5 hours to 1.5 hours before the target bedtime.

14. The method of claim 6, wherein the administering includes administering about 20 mg of tasimelteon.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Mallinckrodt
Merck
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.